Akums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and 15% Adj PAT growth https://www.taxtmi.com/news?id=33347 Akums disclosed consolidated quarterly results showing year on year increases in adjusted EBITDA and adjusted PAT driven by improved CDMO profitability, alongside a decline in total income and reduced API EBITDA losses; the company announced a significant commercial supply contract to expand its European CDMO footprint and reported in licensing activity to support future branded product growth. en-us Sat, 08 Feb 2025 14:46:03 +0530 Sat, 08 Feb 2025 14:46:03 +0530 TaxTMI RSS Generator Akums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and 15% Adj PAT growth https://www.taxtmi.com/news?id=33347 Akums disclosed consolidated quarterly results showing year on year increases in adjusted EBITDA and adjusted PAT driven by improved CDMO profitability, alongside a decline in total income and reduced API EBITDA losses; the company announced a significant commercial supply contract to expand its European CDMO footprint and reported in licensing activity to support future branded product growth. News - Sat, 08 Feb 2025 14:46:03 +0530 https://www.taxtmi.com/news?id=33347